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H
ealth risks related to tobacco use
have been well established for 50
years, with diseases including lung
cancer, other malignancies, and cardio-
vascular diseases linked to smoking and
causing early mortality in current and
former smokers (1–4). Yet cigarette
smokingremainshighlyprevalentinboth
thedevelopinganddevelopedworlds(5).
Smoking uptake typically occurs in the
teenage years, when risk-taking behavior
is the norm and peer pressure is a power-
ful predictor of behavior. The prevalence
ofchronicdiseases,suchashypertension,
diabetes, respiratory disease, arthritis,
andcardiovasculardisease,islowinteen-
agers and young adults but increases into
middle-age and older adulthood (6–9).
Conversely, in developed countries like
the U.S., smoking prevalence peaks in
young adults and decreases as the popu-
lation ages, because people stop smoking
or die (with current smokers dying at a
faster rate than former or never smokers)
(10). Most of the adult population in the
developed world who are current smok-
ers grew up in an environment where the
risks of smoking were well established
and well known to the public. So why do
our adult patients, many of whom have
diseaseseitherrelatedtotobaccosmoking
or complicated by smoking, ﬁnd it difﬁ-
cult to quit?
This question has been a vexing one
to both clinicians and public health prac-
titionerssincetheadverseaffectsofsmok-
ing became known to us. There are
divergent truths. On one hand, in most
developed countries, the majority of peo-
ple who have ever smoked in their life-
time have successfully quit (11). On the
other hand, many people with chronic
diseases that are clearly worsened by cig-
arette smoking are unable to quit. So why
can some patients quit quickly and easily
while other patients smoke right up to
their premature death?
The answers to this question are per-
haps as varied as our patient population,
with a variety of different factors that are
important. Tobacco use has many fea-
tures of a complex chronic illness such as
diabetes.Forexample,indiabetes,thein-
cidence,severity,andoutcomesofdisease
is related to a variety of genetic, environ-
mental, and lifestyle factors (i.e., parental
history of disease, exposure to infections,
comorbid disease, obesity, etc.). In ciga-
rette smoking, there is evidence that ge-
netic factors, early life exposures, and
environmental factors (i.e., living in an
area that restricts smoking or heavily
taxes cigarettes) inﬂuences smoking up-
take and cessation (10,12).
One reality is that not all of our pa-
tients, even in the face of debilitating dis-
ease, want to stop smoking. While a large
proportionofcurrentsmokerswouldlike
to stop smoking, particularly if they have
developed a disease due to or worsened
by smoking, there remains a signiﬁcant
minority of smokers who have no desire
to quit (10,13). The reasons for this are
not completely clear and may be, in large
part, related to the addictive nature of
smoking that will be discussed below.
Other potential explanations are that
these patients perceive that, at least for
them, the “beneﬁts” of smoking outweigh
the“risks”(14).Someofthesepatientsare
completely aware of the problems related
tosmokingbuthavedecidedthattheyare
so unhappy if not smoking that they de-
cide to continue. In other cases, people
may have developed a terminal disease,
such as metastatic lung cancer, and the
“comfort” of continued smoking out-
weighs, at least for them, any beneﬁts of
stopping.
Among the 60–80% of our adult
smoking population who would like to
quit, what are the factors that keep them
smoking? In the U.S. in 2006, the median
prevalence of current daily smokers who
quit for at least 1 day was 58.6% (10).
Long-term abstinence rates, however, are
poor. Among smokers who attempt to
quit on their own, 80% relapse within 1
month and 97% relapse within 6 months
(15).Smokerstypicallyneedfourormore
quit attempts before they achieve long-
termabstinence(16).Eveninrecenttrials
usinghighlymotivatedpatients,validated
relapse rates at 12 months ranged from
77%intheactivetreatmentgroupto92%
in the placebo group (17,18). These and
otherstudiesprovidestrongevidencethat
thefactorsthatkeepsmokerssmokingare
very powerful and that cigarettes are, in
fact, addictive (19).
What are the components of this ad-
diction that has many features of a
chronic illness? The addiction itself has
physiological, psychological, and behav-
ioral components that will be addressed
below.Centraltoaddictiontocigarettesis
the role of nicotine, the pharmacologic
agent that is critical in maintaining smok-
ing. While burning cigarettes emit over
4,000 different agents (2), the evidence
that nicotine is the main culprit in main-
taining addiction is strong. For example,
cigarettes from which nicotine has been
removed or those with ultra-low levels of
nicotine have never been widely accepted
by the smoking public, whereas chewing
tobacco and snuff, both of which deliver
largeamountsofnicotine,arewidelyused
(20). Nicotine meets criteria for drug de-
pendency in that it promotes compulsive
use, has psychoactive effects, and rein-
forces its own use (19,21).
Physiological dependence on nico-
tine is thought to be related to its action
onnicotinicacetylcholinereceptorsinthe
brain (20). Activation of these receptors
results in the release of neurotransmit-
ters—most importantly, dopamine, but
also norepinephrine, acetylcholine, -en-
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to some of the “positive” effects of smok-
ing, such as pleasure, arousal, and the re-
duction of anxiety and tension. Repeated
exposure to nicotine over time, such as
occurs in habitual smokers, results in
both a desensitization of these receptors
to nicotine and an increase in the number
ofreceptors(23).Duringperiodsofabsti-
nence, such as while sleeping, it is
thought that these desensitized receptors
may recover and elicit symptoms of
“withdrawal.” These acute symptoms in-
clude irritability, depressed mood, anxi-
ety, difﬁculty concentrating, insomnia,
and craving for tobacco, among others
(24). Thus, the acute changes that occur
when a person stops smoking suddenly
provide a powerful reinforcement to start
smoking again.
The behavioral component of addic-
tion to cigarettes is a powerful reinforcer
ofthephysiologicalcomponentofthisad-
diction. People smoke in certain situa-
tions, such as while driving, while
drinking a cup of coffee in the morning,
or while out at a bar with friends. They
also may smoke in response to certain
cues, such as feeling stressed or annoyed
(20).Inaddition,theactualactofinhaling
smokefromacigaretteishighlyritualized
and repeated hundreds of times per day
and thousands of times per year. It is
thought that this conditioning may be a
major factor in relapses that occur in pa-
tients months to years after they stop
smoking—an extremely stressful situa-
tion and nicotine receptors that have re-
turned to their normal state of sensitization
maybeenoughforthepatienttostartsmok-
ing again.
The psychological component of
smoking addiction may be one of the
mostchallengingtodealwith(25).People
who advance beyond the experimenta-
tionstageofsmokingmayhaveadditional
reasonsfordoingso,suchasundiagnosed
psychiatric disease, a desire to lose or
maintain weight, or other factors (26).
The threshold for both initiating and
maintain smoking may be different in at-
riskindividuals.Inaddition,theremaybe
genetic or early life exposure factors that
predispose people to becoming and stay-
ing smokers, although this ﬁeld is contro-
versial (27,28).
Whilenicotineistheprimarysubstance
responsible for addiction in smokers, to-
bacco smoke also contains thousands of
other chemicals that may contribute to this
addiction. Some of these, such as acetalde-
hyde, result from tobacco industry manip-
ulation of sugar levels in tobacco, with the
end result being enhancement of nicotine’s
physiological properties (29,30).
In conclusion, there are a variety of
factorsthatcontributetowhyourpatients
are unable to stop smoking. These range
from some people believing that the ben-
eﬁtsofsmokingoutweightherisks,tothe
very powerful physiological, behavioral,
and psychological factors that keep peo-
ple smoking. Strategies to help our pa-
tients stop smoking must address all of
these factors.
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